Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia

Koutaro Takamatsu, Shunya Nakane, Shigeaki Suzuki, Takayuki Kosaka, Satoshi Fukushima, Toshihiro Kimura, Azusa Miyashita, Akihiro Mukaino, Shiori Yamakawa, Keisuke Watanabe, Masatoshi Jinnin, Yoshihiro Komohara, Hironobu Ihn, Yukio Ando

研究成果: Article査読

14 被引用数 (Scopus)

抄録

Immune checkpoint inhibitors sometimes cause neuromuscular adverse events. Although a few cases of myasthenia gravis with hyperCKemia triggered by immune checkpoint inhibitors have been described, conclusive evidence remains limited. We conducted a systematic review of published cases of myasthenia gravis with hyperCKemia related to immune checkpoint inhibitors. Moreover, we tested anti-striational antibodies in the case of myasthenia gravis with myositis after nivolumab administration. We located 17 published case reports. Anti-striational antibodies were tested in six cases and five cases were positive. Our systematic analyses revealed poor prognosis in myasthenia gravis combined hyperCKemia with immune checkpoint inhibitors.

本文言語English
ページ(範囲)1421-1427
ページ数7
ジャーナルAnnals of Clinical and Translational Neurology
5
11
DOI
出版ステータスPublished - 2018 11

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

フィンガープリント 「Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル